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Trachoma is a poorly understood immunofibrogenic disease process, initiated by Chlamydia trachomatis.
Differences in conjunctival gene expression profiles between Ethiopians with trachomatous trichiasis (with
[TTI] or without [TT] inflammation) and controls (C) were investigated to identify relevant host responses.
Tarsal conjunctival swab samples were collected for RNA isolation and C. trachomatis PCR. Transcriptome-
wide microarray experiments were conducted on 42 samples (TTI, n  13; TT, n  15; C, n 14). Specific
results were confirmed by using multiplex quantitative reverse transcription-PCR for 16 mRNA targets in an
independent collection of case-control samples: 386 case-control pairs (TTI, n 244; TT, n 142; C, n 386).
The gene expression profiles of cases were consistent with squamous metaplasia (keratins, SPRR), proinflam-
matory cytokine production (IL1, CXCL5, and S100A7), and tissue remodeling (MMP7, MMP9, MMP12, and
HAS3). There was no difference in the level of IFN between cases and controls. However, cases had increased
INDO, NOS2A, and IL13RA2 and reduced IL13. C. trachomatis was detected in 1/772. Cases show evidence of
ongoing inflammation and tissue remodeling, which were more marked where clinical inflammation was also
present. Significantly, these processes appear to be active in the absence of current C. trachomatis infection.
There was limited evidence of a TH1 response (INDO and NOS2A) and no association between a TH2 response
and cases. The epithelium appears to be actively involved in late cicatricial stages of trachoma through the
production of proinflammatory factors (IL1, CXCL5, and S100A7). Longitudinal studies are needed to
investigate which etiological factors and pathways are associated with progressive scarring and whether simply
controlling chlamydial infection will halt progression in people with established cicatricial disease.
Trachoma is the leading infectious cause of blindness world-
wide (57). The disease process starts in early childhood with
recurrent conjunctival infection by the bacterium Chlamydia
trachomatis. This triggers a florid chronic inflammatory re-
sponse characterized clinically by papillary hypertrophy and
lymphoid follicles (active trachoma). In later life, after re-
peated episodes of infection and inflammation, scar tissue be-
gins to accumulate within the conjunctiva, particularly that
lining the upper eyelid. This causes eyelid distortion leading to
the rubbing of lashes on the cornea (trichiasis). Ultimately,
blinding corneal opacification develops.
The tissue damage in trachoma is primarily due to the hu-
man immune response rather than direct damage by the patho-
gen. Chlamydial infection is limited to the superficial conjunc-
tival epithelium, while the inflammatory response extends into
the deeper subepithelial layers (23). Moreover, clinical inflam-
mation is often found in the absence of detectable infection
(11). Studies of C. trachomatis infection in a monkey model
demonstrated that after a primary infection the inflammatory
phenotype could be induced by inoculating the conjunctiva
with the C. trachomatis HSP60 antigen (66). There are some
data on the immunological response in early active trachoma;
however, there is limited information about the cicatricial
stage (10, 28, 30, 44, 45). It is unknown which fibrogenic path-
ways are important to this disease process and what drives
them. There are some data which show that individuals who
have repeated severe inflammation in childhood are more
likely to develop scarring complications in later life (16, 71).
However, there are no longitudinal data that directly demon-
strate that repeated C. trachomatis infection is needed for
progressive scarring in later life, although scarring complica-
tions are generally more frequent and severe in regions where
there is a high prevalence of active disease or C. trachomatis
infection.
Previous work on trachoma and analogous disease processes
has suggested a number of potential mechanisms for the de-
velopment of scarring. It was suggested that a predominantly
TH1 type response may be protective and that a predominantly
TH2 response may be associated with the development of scar-
ring (28). In addition, there is mounting evidence for the im-
portance of TH2 responses in other infectious diseases that
produce scarring such as schistosomiasis, which may be medi-
ated by interleukin-13 (IL-13) and alternative macrophage ac-
tivation (73). There are also some data indicating that factors
such as the matrix metalloproteinases may be involved in the
tissue remodeling process in trachoma (9, 10, 21, 30).
Azithromycin can be effective in controlling chlamydial in-
fection in communities where coverage rates are high (61).
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However, there are significant obstacles to its effective regular
long-term delivery. Similarly, improved control of genital chla-
mydial infection can be achieved through screening programs;
however, these are expensive, and uptake is low. Therefore, an
antichlamydial vaccine would be useful (64). Trachoma vaccine
trials in the 1960s induced short-lived, serovar-specific protec-
tion with whole-organism vaccines (25, 69). Furthermore, in
some trials vaccination was thought to be associated with more
severe disease, suggesting immunopathological tissue damage
(63). Therefore, a critical issue is whether an antichlamydial
response can be induced without provoking fibrosis. A better
understanding of how chlamydial infections damage tissue and
cause fibrosis is necessary for the development of a safe vac-
cine that will prime the immune system to produce nonfibro-
genic responses.
To further our understanding of scarring trachom, we inves-
tigated the conjunctival gene expression profile in a group of
Ethiopian individuals with established trachomatous scarring
and trichiasis (with or without inflammation). These cases were
compared to control subjects from the same communities. We
initially performed microarray analysis on a limited set of sam-
ples. Subsequently, quantitative reverse transcription-PCR
(RT-PCR) was used to validate microarray findings and ex-
plore specific hypotheses in a large case-control series.
MATERIALS AND METHODS
Ethical permission. This study was approved by the National Health Research
Ethics Review Committee, Ministry of Science and Technology of Ethiopia; the
London School of Hygiene and Tropical Medicine Ethics Committee; and the
Emory University Institutional Review Board. Informed consent was obtained
prior to enrolment of each subject. This study adhered to the tenets of the
Declaration of Helsinki.
Study participants. Individuals with trachomatous trichiasis were recruited
during a surgical campaign in Amhara Region, Ethiopia. Control subjects, who
did not have either trichiasis or significant conjunctival scarring, were recruited
from the same communities as the cases. We recruited three groups of subjects
(i) patients with trichiasis and inflammation (TTI), (ii) patients with trichiasis but
no conjunctival inflammation (TT), and (iii) controls without trichiasis or signif-
icant conjunctival scarring (C). A much larger number of trichiasis cases (both
TTI and TT) and matched controls were recruited for real-time PCR assessment
of gene expression. Where possible, controls were of the same sex, similar age
(10 years) and came from the same community as their matched case.
Clinical assessment and sample collection. All participants were examined for
clinical signs of trachoma, graded using 2.5 binocular loupes according to the
detailed World Health Organization (WHO) trachoma grading system (15).
Trichiasis was defined as lashes touching the eye or clear evidence of epilation of
trichiatic lashes. Conjunctival inflammation was considered significant if there
were prominent papillae and/or haziness of the upper tarsal blood vessels (P2/P3)
(15). Conjunctival scarring was considered significant if there were easily visible
moderate or severe scars (C2/C3) on the upper tarsal conjunctiva (15). The
conjunctiva was anesthetized with preservative-free proxymetacaine 0.5% eye
drops (Minims; Chauvin Pharmaceuticals). Two conjunctival swab samples were
collected from the upper tarsal conjunctival surface (Dacron polyester-tipped
swab; Hardwood Products Company). The first was collected for RNA isolation
and placed directly into a tube containing 0.3 ml of RNAlater (Ambion). The
second swab was collected for C. trachomatis PCR and placed in a dry tube.
Samples were kept on ice packs until frozen later the same day at 20°C.
Microarray experiments. RNA was extracted from swab samples by using an
RNeasy Micro kit (Qiagen, Crawley, United Kingdom) according to the manu-
facturer’s instructions. Total RNA was assessed for concentration and quality on
a NanoDrop ND-1000 (Thermo Fisher Scientific, Loughborough, United King-
dom) and a Bioanalyser (Agilent Technologies, Queensferry, United Kingdom).
Microarray experiments were performed at Cambridge Genomic Services, Uni-
versity of Cambridge, using the HumanWG-6 v3.0 Expression BeadChip (Illu-
mina, San Diego, CA) according to the manufacturer’s instructions. Briefly,
RNA underwent linear amplification using the Illumina TotalPrep RNA ampli-
fication kit (Ambion, Warrington, United Kingdom) according to the manufac-
turer’s instructions. The cRNA was checked on a NanoDrop and Bioanalyser for
concentration and to verify the success of amplification. If the concentration was
below 150 ng/l, this was increased by using a SpeedVac (Thermo Fisher Sci-
entific). cRNA was hybridized to the HumanWG-6 BeadChip overnight. The
next day the BeadChips were washed and stained. Finally, the chips were scanned
by using a bead array reader (Illumina).
Quantitative RT-PCR. The abundance of 16 selected transcripts was estimated
by quantitative RT-PCR. Gene targets (see Table 6) were chosen to address the
hypothesized roles of TH1/TH2 balance (IFNG, IL13, and 1L13RA2), classical
and alternative macrophage activation (NOS2A and ARG1), and matrix metal-
loproteinases (MMP7, MMP9, MMP12, and HAS3) in the fibrotic process. In
addition, four targets (S100A7 [psoriasin], CXCL5, HAS3, and IL19) identified in
the microarray experiment as having marked increase in expression in cases, and
the potential to be important in this disease process, were also selected for
quantitative RT-PCR estimation.
Total RNA was extracted from the swab samples using the RNeasy Micro kit
(Qiagen). Reverse transcription was performed by using a QuantiTect reverse
transcription kit (Qiagen) according to the manufacturer’s instructions. This
contains a mix of oligo(dT) and random primers. Multiplex real-time quantita-
tive PCR was performed on a Rotor-Gene 6000 (Corbett Research, Cambridge,
United Kingdom) using the QuantiTect Multiplex NoROX kit (Qiagen), accord-
ing to the manufacturer’s instructions. Multiplex assays of up to four separate
targets (including HPRT-1 as the reference gene) were designed by Sigma Life
Science (Sigma Primer and Probe Design Service) using Beacon Designer 7.60
(Premier Biosoft International, Palo Alto, CA). The thermal cycle protocol used
the following conditions: 95°C for 15 min, followed by 45 cycles of first denatur-
ation at 94°C for 30 s and then annealing and extension at 60°C for 30 s.
Fluorescence data was acquired at the end of each cycle. The relative efficiency
of the component reactions was assessed using standards containing all targets in
a sequence of 10-fold serial dilutions. Reactions were performed in duplicate, in
a total volume of 25 l, which contained 2 l of sample or standard. Probe and
primer sequences are available on request.
C. trachomatis detection. Conjunctival swab samples collected from the sub-
jects in the RT-PCR case-control study were tested for C. trachomatis DNA by
using a PCR-based assay (Amplicor CT/NG Test; Roche) with previously de-
scribed modifications (11). We did not collect DNA swabs from individuals in the
microarray component of the study.
Microarray analysis. Quality control checks on the microarray data were made
using GenomeStudio (Illumina). Sample independent controls were used to
assess the success of the microarray process (hybridization, stringency, biotin
control, and negative controls). Sample dependent controls examined the inten-
sities of reference genes and the average intensity of all probes on each strip of
the array. The data were transferred to Lumi (www.bioconductor.org), an open-
source software package written in R (www.r-project.org), for the analysis of
Illumina microarray data (19). Additional checks on the correlation between
replicates and the intensity distribution were made. Nonsupervised clustering
was performed to identify potential outliers. Transcripts were selected for anal-
ysis if they were expressed in at least one sample and they were significantly
different from the negative controls at the 1% significance level. The data were
transformed using the variance stabilization transformation and then normalized
using quantile normalization in Lumi (40). Normalized data were examined by
using the open-source R-based package LIMMA (www.bioconductor.org) in
three pairwise comparisons: TTI versus C, TT versus C, and TTI versus TT (60).
We corrected for multiple testing by using the Benjamini-Hochberg method for
adjusting the P value and thereby controlling the false discovery rate (3). Gene
enrichment analysis of gene ontology terms and pathways were performed for
the three pairwise comparisons using DAVID (v6.7; http://david.abcc.ncifcrf.gov)
and GeneGO (GeneGO, St. Joseph, MI) (18, 32). Enriched gene ontology terms
were identified by assessing the proportion of genes in a particular grouping that
were either upregulated (fold change, 1.5) or downregulated (fold change,
0.66) with an adjusted P value of 0.05.
The microarray data discussed in this publication have been deposited in
NCBI’s Gene Expression Omnibus and are accessible through GEO Series
accession number GSE23705 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc
GSE23705).
Quantitative RT-PCR analysis. The transcript abundances for genes of inter-
est were standardized relative to that of HPRT1 in the same reaction using the
CT method and were successfully normalized by log10 transformation (41). An
overall comparison of the mean values across the three different clinical catego-
ries was made using one-way analysis of variance. Paired comparisons between
clinical categories were made using either paired or unpaired Student t tests as
appropriate. Bonferroni correction for 48 multiple comparisons gave a critical
significance threshold value of P  0.001.
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RESULTS
Study participants. All participants were of Amharan Ethi-
opian ethnicity. We recruited and collected samples from 45
individuals for the microarray study. The mean RNA concen-
tration in the extract was 76 ng/l (standard deviation [SD] 
23; range, 26 to 125 ng/l). Three samples were not included in
the microarray experiment because their RNA concentration
was insufficient (2 TTI and 1 C). The numbers, age, and gender
profiles of the three clinical groups (TTI, TT, and C) are shown
in Table 1. None of the control subjects in the microarray
experiment had any visible conjunctival scarring.
For the quantitative RT-PCR component of the present
study we recruited 772 individuals: 386 trichiasis cases (TT,
n  142; TTI, n  244) and 386 controls, whose demographic
and clinical characteristics are shown in Table 2. The severity
of endemic trachoma in this Ethiopian population is such that
there are relatively few adults who are totally free of any tarsal
conjunctival scarring. Therefore, to meet other matching cri-
teria for controls (location, age, and sex), we accepted controls
with minor degrees of conjunctival scarring (WHO C1 or mild
C2).(15). The vast majority of individuals (762 of 772) in the
present study lived in districts that have been mass treated with
azithromycin for trachoma control during the year prior to
surgery with an average population coverage of 77% (The
Carter Center, Ethiopia). There had been no treatments dur-
ing the 3 months prior to when sampling started.
Microarray quality control and data selection. The microar-
ray internal sample-independent quality control tests all
yielded “good” results. Reference genes performed well, indi-
cating that there was no template degradation. Of the 44,803
probe sets that can be detected by the Human WG-6 microar-
ray, 17,214 were selected for normalization and analysis.
Global gene expression and clinical state. To assess the
extent to which global gene expression profiles could distin-
guish the clinical groups, a 4242 matrix of the Pearson cor-
relation coefficients of global gene expression for each pair of
subjects was constructed (Fig. 1). Each row and column cor-
responds to an individual subject and the entry in the ith row
and jth column being the Pearson correlation rij between the
global expression profiles of individuals i and j. The matrix was
reordered so that subjects whose profiles were most similar
were placed in adjacent rows and columns and a hierarchical
tree of similarity constructed (Fig. 1). This hierarchical tree
had two main branches. All individuals with TTI were found in
branch 1, and all normal controls were in branch 2. The cases
with TT (without inflammation) were found in about equal
proportion in both branches. Within branch 1 the TTI and the
TT cases mostly segregated into separate clusters. Similarly, in
branch 2 the controls and the TT cases generally segregated.
Differentially regulated genes in different clinical states. For
all 17,214 probe sets detected by microarray and selected for
analysis expression levels were compared between the clinical
groups: TTI versus C, TT versus C, and TTI versus TT. Tran-
scripts found to be at an increased or a decreased abundance
relative to the C group, or to the TT group in the case of TTI
versus TT, were filtered with different adjusted P value thresh-
olds (Table 3). The numbers of transcripts unique to each
comparison with a 2-fold increase or decrease in abundance
are shown in Fig. 2. In this Venn diagram, the origins of a
selection of potentially interesting transcripts are indicated.
The most numerous differences were between TTI and C, with
less differential regulation occurring between TT and C and
between TTI and TT cases. Selected transcripts of interest
identified by microarray analysis are shown in Table 4 for each
of the comparisons, along with their fold changes and adjusted
P values. Various categories of genes showed differential ex-
pression: cell surface markers (HLA-DRB1, CD19, and
CD24), cytokines/chemokines (IL-1B, IL-19, CXCL5, CCL5,
TABLE 1. Demographic characteristics of subjects in microarray
study grouped by clinical phenotypea
Parameter C (n  14) TTI (n  13) TT (n  15)
No. of male
subjects (%)
7 (50) 2 (15) 6 (40)
No. of female
subjects (%)
7 (50) 11 (85) 9 (60)
Mean age in yr
(95% CI)
43.5 (36.3–52.2) 40.8 (32.2–51.6) 56.1 (50.0–93.0)
a Subject group: TTI, trichiasis with inflammation; TT, trichiasis without in-
flammation; C, control; n, number of subjects.
TABLE 2. Demographic and clinical characteristics of cases and
controls in the quantitative RT-PCR studya
Parameter
Cases (n  386) Controls (n  386)
No. % No. %
No. of female subjects 290 75.1 269 69.7
No. of subjects at age:
40 yr 90 23.3 107 27.7
40–49 yr 102 26.4 99 25.6
50–59 yr 94 24.4 84 21.8
60 yr 100 25.9 96 24.9
Mean (95% CI)b 49.6 48.2–51.0 48.0 46.6–49.4
Mean BMIc (95% CI) 19.7 19.4–19.9 20.5 20.1–20.7
Trichiasis (no. of lashes)
None 386 100
None (epilating) 60 15.5
1–4 128 33.2
5–9 115 29.8
10–19 44 11.4
20 39 10.1
Mean (95% CI) 8.8 7.3–10.2
No. of subjects with
conjunctival
inflammation
P0 29 7.5 242 62.7
P1 113 29.3 136 35.2
P2 187 48.4 8 2.1
P3 57 14.8 0 0.0
No. of subjects with
conjunctival
scarring
C0 105 27.2
C1 4 1.0 235 60.9
C2 239 61.9 46 11.9
C3 143 37.1
a The percent values represent the percent total number. Range values indi-
cate 95% CI values.
b Student t test, P  0.10.
c Body mass index (BMI) data were available on 384 cases and 240 controls
(Student t test, P  0.0001).
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and CCL20), immune response effector molecules (S100A7,
DEFB4, PLUNC, NOS2A, DUOX2, and INDO), extracellular
matrix regulators (MMP7, MMP9, MMP12, SPARCL, and
CEACAM5), and keratinization components (SPRR2A,
SPRR2D, KRT6A, and KRT6B). Factors involved in the in-
nate immune response were particularly prominent (S100A7,
CXCL5, DEFB4, PLUNC, NOS2A, and SAA1). There was
some evidence of activated TH1 responses in cases (INDO,
DUOX2, and NOS2A). There was no evidence of increased
abundance of transcripts associated with a TH2 type response
FIG. 1. Global gene expression. A correlation matrix for the global gene expression profile (all genes) between all pairs of samples. Samples
are ordered into a hierarchical tree for similarity. Sample type: TTI, trichiasis with inflammation (red); TT, trichiasis without inflammation
(orange); C, control (green).
TABLE 3. Number of regulated genes in each of three comparisons, filtered by different adjusted P value thresholdsa
P value threshold
TTI vs C TT vs C TTI vs TT
No. of genes % No. of genes % No. of genes %
Adjusted
0.05 9,003 52 4,141 24 4,677 27
0.01 6,766 38 2,041 12 1,644 9
0.001 4,423 25 841 5 189 1
Filteredb
Upregulated genes 2,022 410 128
Downregulated genes 2,401 431 61
a The comparisons included groups TTI versus C, TT versus C, and TTI versus TT. The percent values are of the total number of genes selected for normalization
and analysis (n  17,214).
b That is, filtered at the adjusted P value of 0.001.
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in cases. Table S1 in the supplemental material presents the
fold changes and adjusted P values for all targets where there
was a 2-fold increase or decrease.
Gene enrichment analysis. The results of gene enrichment
analysis performed using DAVID and GeneGO are shown in
Table 5. In comparing samples from trichiasis cases (with or
without inflammation), we found that DAVID identified sig-
nificant enrichment of gene ontology (GO) terms involved in
the development of a keratinized/cornified squamous epithe-
lial surface in individuals with trichiasis (irrespective of the
presence of inflammation). The top five GO terms for the
comparisons of the TT or TTI groups with the C group reflect
these processes, although there is considerable overlap in the
specific genes included in these terms. Where clinical inflam-
mation was also present, additional GO terms related to im-
mune responses were also enriched. Pathway analysis using
GeneGO identified a similar pattern of changes with trichiasis
associated with cytoskeleton remodeling (keratin, WNT path-
way) and regulation of cell cycle components and inflamed
conjunctiva associated with an immunological response.
Quantitative RT-PCR analysis of gene expression. Quanti-
tative real-time RT-PCR was performed for the 16 gene ex-
pression targets (Table 6) on all 772 cases and controls. The
geometric means, the 95% confidence interval (95% CI) val-
ues, and statistical comparisons of the three clinical categories
are shown in Table 6. The fold changes measured by the
microarray experiment were highly correlated with those mea-
sured by quantitative RT-PCR: correlation coefficient 0.88,
P  0.0001. A high proportion (42%) of samples did not have
detectable expression of IL19. However, there was a significant
difference (odds ratio, 9.4; 95% CI, 6.7 to 13.1; P  0.001) in
the proportion expressing IL19 between the TT/TTI cases
(319/386 [83%]) and controls (130/386 [34%]]).
There was no evidence that IFN	 was differentially regulated
between cases and controls; however, there was significantly
increased expression of both INDO and NOS2A. The expres-
sion of IL13 was lower in cases compared to controls, partic-
ularly where inflammation was also present. Conversely, the
expression of the decoy receptor IL13RA2 was increased in the
cases compared to the controls. The ratio of IL13/IL13RA2
expression was markedly reduced in cases relative to controls.
We found the expression of ARG1 to also be reduced in cases
relative to controls.
IL1B, CXCL5, and S100A7 were expressed at significantly
increased levels in cases compared to controls. Cases with
inflammation (TTI) were found to have increased expression
of these three factors relative to cases without inflammation;
however, the critical significance level of P  0.001 was not
reached. We did not find a variation in the expression of IL10
between cases and controls. The extracellular matrix regulators
MMP7, MMP9, MMP12, and HAS3 were increased in cases
relative to controls.
We examined whether there was any evidence of differential
gene expression between controls with mild conjunctival scar-
ring and controls without any sign of scarring. The only differ-
ence was for NOS2A, which was slightly increased in the con-
trols with mild scarring (fold change, 1.54; P  0.0001).
C. trachomatis PCR. All 772 dry samples collected from
individuals in the case-control study were tested for C. tracho-
matis by PCR. Of these, only one sample was positive, five were
consistently inhibited on retesting, and the remaining 766
tested negative. All positive and negative controls performed
normally. With the exception of the five inhibited samples, all
specimen internal control tests were positive.
DISCUSSION
The pathophysiology of scarring trachoma is poorly charac-
terized in terms of the immunological factors and fibrogenic
pathways involved. In the present study, using transcriptome-
wide gene expression analysis, we found marked differential
gene expression in the conjunctiva of individuals with signifi-
cant trachomatous scarring and trichiasis compared to controls
with minimal or no conjunctival scarring. Gene enrichment
FIG. 2. Differentially expressed genes with a 2-fold change for
the three comparison pairs (TTI versus C, TT versus C, and TTI versus
TT). (a) Upregulated genes; (b) downregulated genes. Selected genes
of interest are shown.
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analysis indicates that the most prominent changes were in the
nature of the epithelium, suggestive of squamous metaplasia.
Second, trachomatous scarring and trichiasis, particularly in
the presence of clinically visible conjunctival inflammation, was
associated with various proinflammatory factors, characteristic
of an activated innate immune response. Third, there was very
limited evidence of an ongoing TH1 but not TH2 response in
scarred conjunctiva. Finally, there was evidence of cytoskeletal
remodeling, including enrichment of the profibrotic WNT
pathway and increased expression of various regulators of the
extracellular matrix. We found that the results for various
targets measured by quantitative PCR in a large case-control
series were consistent with the microarray data.
Squamous metaplasia of the conjunctival epithelium. An
important clinical feature of cicatricial trachoma is the trans-
formation of the conjunctival epithelium from healthy mucosa
into a pathologically dry, keratinized surface. Normally, the
tarsal conjunctival surface is formed of a nonkeratinized strat-
ified epithelium. The superficial cells tend to be cylindrical in
shape, and there are scattered goblet cells. In advanced tra-
chomatous scarring, the epithelium is thinned and transformed
into a keratinized, stratified, squamous epithelium with loss of
goblet cells (1, 4). Squamous metaplasia requires the synthesis
of specific proteins, including small proline-rich proteins
(SPRR) and keratins that are key components of the cornified
envelope. We found significantly increased expression in cases
of several SPRRs (SPRR1A, SPRR2A, SPRR2D, and
SPRR2F) and keratins (KRT6A, KRT6B, KRT6E, KRT17,
and KRT24). This was more marked in clinically inflamed
conjunctiva. Extensive squamous metaplasia is detrimental to
the health of the ocular surface and may contribute to the
development of blinding corneal opacification in trachoma.
Ocular surface squamous metaplasia develops in other con-
junctival disease processes, often in association with chronic
inflammation and dryness, as in, for example, ocular cicatricial
pemphigoid, Stevens-Johnson syndrome, systemic sclerosis,
and alkali burns. It is likely that squamous metaplasia is a
nonspecific response to injury or inflammation. In experimen-
tal models of dry eye disease there is an influx of inflammatory
cells, particularly CD4 lymphocytes, and upregulation of
SPRRs (SPRR-1, SPRR-2) under the influence of proinflam-
matory cytokines, particularly IL-1
 and gamma interferon
(IFN-	) (17, 39).
Mucins are important components of the ocular surface.
Their hydrophilic properties allow surface wetting, and they
provide a physical barrier to bacterial invasion (42). We found
some changes in the expression of several mucins in TT cases.
There was increased expression of MUC1 and MUC4, which
are produced by epithelial cells and attach to the surface mem-
brane. In addition, there was a nonsignificant increase in the
expression of MUC5A, which is a large soluble protein released
from goblet cells. MUC7 expression was reduced, although the
significance of this is unclear since this is primarily derived
from the lacrimal gland. Increased expression of these mucins
may be to compensate for a dry ocular surface.
Proinflammatory response. Chronic conjunctival inflamma-
tion is considered to be a key event in the pathophysiology of
trachomatous scarring. Children with active trachoma, partic-
ularly severe inflammatory trachoma (TI), are at increased risk
of developing the scarring complications of this disease in later
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TABLE 5. Results of gene set enrichment analysisa
Comparison
Gene Ontology terms (DAVID) Gene-GO
N Name FC P Pathway P
TTI vs C 104 GO:0007398ectoderm
development
4.04 1.28  1009 Cytoskeleton remodeling–keratin
filaments
9.60  1012
GO:0008544epidermis
development
4.06 5.14  1009 DNA damage–ATM/ATR regulation of
G1/S checkpoint
1.41  1010
GO:0031424keratinization 8.03 1.67 1007 Cell cycle–the metaphase checkpoint 8.65 1010
GO:0030216keratinocyte
differentiation
6.09 3.46  1007 Cytoskeleton remodeling–cytoskeleton
remodeling
2.04  109
GO:0009913epidermal cell
differentiation
5.58 9.93  1007 Apoptosis and survival–TNFR1
signaling pathway
5.47  109
GO:0006955immune response 2.08 1.45 1006 DNA damage–NHEJ mechanisms of
DSB repair
9.72  109
GO:0030855epithelial cell
differentiation
3.77 5.29  1006 Cell cycle–cell cycle (generic schema) 1.02  108
GO:0006952defense response 2.01 2.17 1005 Apoptosis and survival–FAS signaling
cascades
3.27  108
GO:0009611response to
wounding
2.01 9.39  1005 Cell cycle–role of SCF complex in cell
cycle regulation
5.31  108
GO:0009617response to
bacterium
2.83 1.37  1004 Cytoskeleton remodeling–TGF, WNT,
and cytoskeletal remodeling
6.41  108
TT vs C 37 GO:0007398ectoderm
development
10.68 1.89  1027 Signal transduction–AKT signaling 7.97 109
GO:0008544epidermis
development
10.91 2.65  1026 Development–PIP3 signaling in cardiac
myocytes
5.18  108
GO:0030216keratinocyte
differentiation
18.64 2.87  1021 Cell cycle–role of Nek in cell cycle
regulation
5.37  107
GO:0009913epidermal cell
differentiation
17.04 2.43  1020 Transport–RAN regulation pathway 5.82 107
GO:0030855epithelial cell
differentiation
10.85 1.40  1019 Cell cycle–regulation of G1/S transition
(part 1)
1.35  106
GO:0031424keratinization 22.48 6.79 1018 Cytoskeleton remodeling–keratin
filaments
3.40  106
GO:0060429epithelium
development
6.54 5.43  1014 DNA damage–ATM/ATR regulation of
G1/S checkpoint
3.61  106
GO:0018149peptide cross-
linking
12.51 9.62  1005 Cell cycle–nucleocytoplasmic transport
of CDK/cyclins
3.61  106
GO:0007586digestion 5.36 2.64 1004 Cell cycle–spindle assembly and
chromosome separation
5.61  106
GO:0009617response to
bacterium
3.56 5.66  1004 Development–IGF-1 receptor signaling 6.18 106
TTI vs TT 105 GO:0006955immune response 5.07 1.69 1024 Cell adhesion–chemokines and
adhesion
1.80  109
GO:0006952defense response 4.65 2.36 1019 Immune response–CCR3 signaling in
eosinophils
4.79  109
GO:0042330taxis 8.31 4.23  1014 Immune response–immunological
synapse formation
6.28  108
GO:0006935chemotaxis 8.31 4.23 1014 Cytoskeleton remodeling–cytoskeleton
remodeling
1.67  107
GO:0009611response to
wounding
3.83 2.74  1011 Apoptosis and survival–BAD
phosphorylation
2.01  107
GO:0007626locomotory
behavior
5.28 5.57  1011 Development–IGF-1 receptor signaling 3.29 107
GO:0006954inflammatory
response
4.64 3.45  1010 Immune response–IL-10 signaling
pathway
5.74  107
GO:0007610behavior 3.57 9.79 1009 Development–thrombopoietin-regulated
cell processes
7.52  107
GO:0009617response to
bacterium
5.30 1.28  1007 Immune response–IL-4–antiapoptotic
action
7.93  107
GO:0007398ectoderm
development
4.73 1.44  1006 Chemotaxis–leukocyte chemotaxis 1.02 106
a The top-ten gene enrichment terms were identified by using (i) the Database for Annotation, Visualization, and Integrated Discovery (DAVID), v6.7, and (ii)
Gene-GO. FC, fold change. N, number of gene ontology (GO) terms where P  0.05 and fold enrichment was 1.5.
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life (16, 71). In adults with scarring the conjunctiva frequently
appears clinically inflamed, although in many settings C. tra-
chomatis infection is only infrequently detected, as was the
case in our study (12, 62, 72). Individuals with TT or conjunc-
tival scarring (TS) are at increased risk of nonchlamydial bac-
terial infection, which has been associated with clinically visible
conjunctival inflammation.(8, 12).
In the present study we found increased expression of proin-
flammatory mediators in cases (S100A7, S100A12, CXCL5,
CCL20, IL1B, and SAA1). Interestingly, these factors were
significantly raised in cases without clinical inflammation com-
pared to controls, albeit to a lesser extent than in the inflamed
cases. Several factors were characteristic of innate immune
responses. In vitro studies of epithelial cells infected with C.
trachomatis have measured the production of various chemo-
kines and cytokines (52, 56). These experiments have consis-
tently found that C. trachomatis infection triggers the pro-
longed production of a range of proinflammatory mediators,
which are probably very important in the initial innate immune
response to infection (IL-1, IL-1
, IL-6, IL-8, CXCL1,
CXCL2, CXCL5, and CXCL6). It is likely that some of these
mediators are produced by the conjunctival epithelium in vivo,
suggesting that the epithelium is not just an injured bystander
in C. trachomatis infection but is actively involved in the im-
munofibrogenic response (56). It is also likely that nonchlamyd-
ial bacterial infections stimulate the inflammatory response,
especially where there is established tissue disruption caused
by repeated C. trachomatis infection.(10) In addition to the
epithelium, other cells, such as macrophages and neutrophils,
probably contribute to the production of these proinflamma-
tory mediators.
The innate immune response of epithelial cells is triggered
through the stimulation of pattern recognition receptors
(PRRs) by bacterial antigens. These receptors recognize con-
served pathogen-associated molecular patterns (PAMPs).
PRRs, such as the Toll-like receptors (TLRs), detect PAMPs
both on the epithelial cell surface and in the intracellular
compartment. Relatively little is known about the role of PRRs
in human C. trachomatis infection in general, and there are
virtually no data for trachoma. C. trachomatis recognition by
PRRs TLR2 and TLR4 is the most well-characterized path-
way, with in vitro studies indicating that both can detect a range
of C. trachomatis antigens (2, 35, 48). Their specificity appears
to differ; TLR4 detects C. trachomatis lipopolysaccharide
(LPS) and HSP60, while TLR2 appears to detect a ligand
produced by viable C. trachomatis (6). In women, C. tracho-
matis-induced tubal scarring has recently been associated with
genetic variation in TLR2 defined by SNP haplotypes (37). In
a mouse model of C. trachomatis genital tract infection, rec-
ognition of C. trachomatis through TLR2 was associated with
increased production of proinflammatory cytokines (IL-1,
IL-6, MIP-2, and TNF-) and the development of scarring in
the oviduct (14). TLR2-knockout mice developed much less
scarring, although the duration of infection was not affected.
We found increased expression of IL1B in cases of trichiasis
compared to controls, irrespective of clinical inflammation.
The role of IL-1
 has previously been investigated in tra-
choma. Immunohistochemistry of biopsy tissue from children
with active trachoma localized the production of IL-1 and
IL-1
 to the superficial layers of epithelial cells, with some
additional production by stromal macrophages (22). We have
previously reported increased IL1B expression in both active
trachoma and conjunctival scarring (9, 10). In both of these
clinical groups, increased IL1B expression occurred with or
without C. trachomatis infection. In individuals with estab-
lished conjunctival scarring, nonchlamydial bacterial infection
was associated with increased expression of IL1B, suggesting
that such infections can promote a proinflammatory response
(10). Others have also found in a separate population that tear
fluid from people with TTI has increased IL-1
 compared to
TABLE 6. Geometric means and 95% confidence intervals for the expression of each gene by clinical categorya
Gene
C (n  386) TT (n  142) TTI (n  244) TTI vs C TT vs C TTI vs TT
Pd
Mean 95% CI Mean 95% CI Mean 95% CI FC Pb FC Pb FC Pc
IFN	 0.0212 0.0191–0.0235 0.0194 0.0167–0.0225 0.0178 0.0157–0.0203 0.78 0.0433 1.03 0.8282 0.92 0.4293 0.1105
TNF 0.2064 0.1964–0.2169 0.2261 0.2013–0.2539 0.2370 0.2150–0.2613 1.11 0.0767 1.16 0.0403 1.05 0.5474 0.0236
IL1B 0.6248 0.5763–0.6775 1.1038 0.9131–1.3343 1.4000 1.2127–1.6164 2.18 0.0001 1.86 0.0001 1.27 0.0489 0.0001
IL10 0.0361 0.0321–0.0407 0.0429 0.0346–0.0532 0.0418 0.0358–0.0487 1.08 0.4941 1.34 0.0660 0.97 0.8449 0.2055
IL13 0.0018 0.0016–0.0022 0.0012 0.0007–0.0015 0.0009 0.0007–0.0011 0.45 0.0002 0.72 0.0545 0.75 0.3895 0.0001
IL13RA2 0.0083 0.0075–0.0093 0.0184 0.0153–0.0223 0.0178 0.0149–0.0214 2.17 0.0001 2.12 0.0001 0.97 0.7785 0.0001
IL19e 0.00003 0.00002–0.00004 0.0001 0.00007–0.00014 0.0001 0.00009–0.00016 2.98 0.0001 3.10 0.0227 1.29 0.2400 0.0001
ARG1 0.0331 0.0310–0.0353 0.0408 0.0349–0.0476 0.0432 0.0383–0.0489 1.30 0.0007 1.24 0.0109 1.06 0.5599 0.0001
NOS2A 0.7908 0.7247–0.8629 2.0494 1.7665–2.3776 2.4573 2.1770–2.7737 3.28 0.0001 2.36 0.0001 1.20 0.0671 0.0001
INDO 1.0955 0.9907–1.2113 3.4223 2.9046–4.0323 4.3953 3.8411–5.0295 4.10 0.0001 3.02 0.0001 1.28 0.0232 0.0001
CXCL5 0.0070 0.0058–0.0084 0.0248 0.0178–0.0344 0.0419 0.0323–0.0543 6.39 0.0001 3.15 0.0001 1.69 0.0145 0.0001
S100A7 0.3972 0.3568–0.4421 3.4075 2.4726–4.6959 5.8468 4.5231–7.5579 14.61 0.0001 8.69 0.0001 1.72 0.0109 0.0001
MMP7 1.0005 0.9169–1.0917 2.7078 2.2781–3.2186 3.1925 2.8415–3.5868 3.14 0.0001 2.79 0.0001 1.18 0.1079 0.0001
MMP9 0.0340 0.0305–0.0378 0.0570 0.0478–0.0679 0.0633 0.0554–0.0723 1.88 0.0001 1.65 0.0001 1.11 0.3429 0.0001
MMP12 0.4047 0.3662–0.4473 0.7397 0.6247–0.8759 0.8437 0.7329–0.9714 2.08 0.0001 1.84 0.0001 1.14 0.2501 0.0001
HAS3 0.1456 0.1313–0.1613 0.2232 0.1904–0.2619 0.2441 0.2133–0.2793 1.68 0.0001 1.53 0.0001 1.09 0.4136 0.0001
IL13/IL13RA2f 0.1911 0.1556–0.2348 0.0505 0.0340–0.0750 0.0425 0.0330–0.0547 0.20 0.0001 0.28 0.0001 0.84 0.4435 0.0001
a The expression levels are standardized relative to the expression of HPRT1 in the same reaction. FC, fold change (a value of 1 indicates increased expression in
the first clinical category of each comparison compared to the second).
b P values for paired t test. Using the Bonferroni correction, the critical significance threshold level is a P value of 0.001.
c P values for unpaired t test. Using the Bonferroni correction, the critical significance threshold level is a P value of 0.001.
d As determined by analysis of variance of the expression level of the gene across the three clinical categories.
e For IL19, only cases or controls where expression was detected are included.
f That is, the ratio of IL13/IL13RA expression.
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controls (59). There is a growing body of evidence which indi-
cates that C. trachomatis and other nonchlamydial bacterial
infections stimulate the production of IL-1
 through a combi-
nation of PRRs, leading to a cascade of proinflammatory prod-
ucts which both help to combat infection but at the same time
can damage tissues (50, 65). In a number of different scarring
disease processes, IL-1
 has been identified as an important cy-
tokine in fibrogenesis, possibly through the activation of fibro-
blasts either via platelet-derived growth factor or transforming
growth factor 
 (TGF-
; activated via MMP9) (24, 58).
In the present study, CXCL5 was the chemokine with the
greatest increase in expression. CXCL5 induces neutrophil
chemotaxis and activation; it has also been found to induce
fibroblast precursor chemotaxis and differentiation (46). Epi-
thelial cells are probably the main source, although both mac-
rophages and fibroblasts also produce it. A study of a C. tra-
chomatis-infected epithelial cell line found CXCL5 was
produced in abundance and led to neutrophil chemotaxis (74).
Interestingly, there is some evidence that C. trachomatis anti-
gens alone (such as MOMP or LPS) might be sufficient to
stimulate CXCL5 production (74). In our study, CXCL5 ex-
pression was increased in the absence of detectable C. tracho-
matis, raising the question of what might be stimulating its
production. Models of Escherichia coli LPS-induced pulmo-
nary inflammation indicate that CXCL5 is produced by the
epithelium through TLR4-dependent signaling (34). It is
therefore possible that in the context of cicatricial trachoma
other bacterial pathogens could stimulate CXCL5 production
directly or indirectly through other cytokines (IL-1
 and
TNF-) or products of extracellular matrix (ECM) breakdown
(actin) (67).
S100A7 (Psoriasin 1) was the most strongly upregulated
gene in the present study. Initially identified in psoriatic skin
lesions, it is a member of the S100 family, a diverse group of
calcium-binding proteins involved in various processes, includ-
ing cell proliferation and differentiation. It is produced by
keratinocytes and has a proinflammatory, microbicidal action,
promoting production of IL-8, TNF-, CCL3, and CCL20 (75).
S100A7 has been implicated in several disease processes. It is
highly expressed in ductal carcinoma in situ, where it is in-
creased by proinflammatory cytokines (IL-1, IL-6, IL-17, and
TNF-) (70). Similarly, in models of skin inflammation,
S100A7 is produced in response to these cytokines (26).
S100A7 is proposed as a novel biomarker for Alzheimer’s
disease; its concentration in the cerebrospinal fluid and expres-
sion in the brain are increased with increasing severity of dis-
ease (51). It has an important antibacterial action in skin both
directly through a porin-like action on bacterial cell walls and
indirectly through stimulation of the innate immune response.
S100A7 induces neutrophil chemotaxis to sites of infection and
at higher concentration stimulates them to degranulate, pro-
duce reactive oxygen species, and release proinflammatory cy-
tokines (IL-6, IL-8, TNF-, CCL3, CCL4, and CCL20) (75).
The effector cells of the innate immune system (neutrophils,
macrophages, and natural killer cells) are found in abundance
in the conjunctiva of children with active trachomatous inflam-
mation and in adults with trachomatous scarring and inflam-
mation (22). It appears likely that, in established trachomatous
scarring, neutrophil chemotaxis is driven by CXCL5, S100A7,
and IL-1
. Animal models of C. trachomatis infection indicate
that the greater the neutrophil infiltrate found in acute inflam-
mation the more likely scarring complications are to develop
(13, 54). Neutrophils respond to infection in a nonspecific
manner, often damaging uninfected tissue. They release a
range of proinflammatory chemokines/cytokines, augmenting
the inflammatory response, produce reactive oxygen species
and degranulate releasing a variety of molecules, such as
MMP9, which can cause tissue damage. If this inflammatory
response is sustained, extensive tissue damage is followed by
aberrant epithelial repair in the form of scar tissue.
The microarray experiments identified several other mark-
ers suggestive of epithelial cell involvement in an innate im-
mune response, including defensin 
4 and PLUNC. These are
typically nonspecific responses to bacterial infection. Serum
amyloid A1 (SAA1) is an acute-phase protein, deposited at
sites of inflammation. Amyloid deposition has previously been
demonstrated in conjunctival biopsy tissue from individuals
with trachomatous scarring (27).
Adaptive immune responses in scarring trachoma. The res-
olution of C. trachomatis infection is thought to require an
IFN-	-dependent TH1 cell-mediated immune response. A
range of data from animal models and human studies support
this conclusion (5). Nude mice cannot control C. trachomatis
genital tract infection (55); however, this function can be re-
stored by adoptive transfer of C. trachomatis-specific CD4 or
CD8 lymphocytes (53). Murine studies indicate the impor-
tance of IFN-	 in this response (43). We have previously re-
ported increased IFN	 expression in children with active C.
trachomatis infection, but not in those with signs of active
disease in the absence of C. trachomatis infection (9). IFN-	 is
thought to mediate its action through various mechanisms,
including the production of nitric oxide free radicals by iNOS
(NOS2A) and intracellular tryptophan depletion through the
action of IDO (INDO). In our study of conjunctival scarring,
we did not find differences in the expression of IFN	 between
cases and controls by quantitative RT-PCR. However, there
was some limited indirect evidence of a TH1-type response
associated with scarring, in that there was increased expression
of INDO and NOS2A. In addition, DUOX2 was also elevated in
cases; this enzyme is found on epithelial cell surfaces and
produces reactive oxygen species in response to TH1 stimula-
tion.
There is more uncertainty about the role of TH2-type re-
sponses in chlamydial infection and trachoma. Earlier studies
in populations where trachoma is endemic found that people
with established scarring (compared to unscarred controls) had
higher serum anti-C. trachomatis IgG titers and, when their
peripheral blood mononuclear cells were stimulated with C.
trachomatis antigens, these individuals had weaker prolifera-
tion responses and expressed IL-4 more frequently (28, 29).
These observations were thought to be consistent with the
hypothesis that an adverse scarred outcome is associated with
a TH2-type response. However, it was unclear whether this
association simply reflected a weaker TH1 response to infec-
tion, which was therefore more severe and/or prolonged, or
whether TH2 responses directly promoted scarring and blunted
TH1 efficacy.
Recently, there has been considerable interest in the role of
IL-13 in fibrosis in a range of disease processes (73). This TH2
cytokine is thought to promote fibrosis through several mech-
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anisms including the direct stimulation of fibroblasts and the
“alternative activation” of macrophages to produce arginase 1
(ARG1), which is important in the production of collagen. In
contrast, “classically activated” macrophages produce iNOS
(NOS2A) in response to TH1/IFN-	 stimulation. This opposes
the profibrotic action of IL-13.
We did not find any evidence of activation of TH2 pathways
in the microarray experiments. In addition, by quantitative
RT-PCR, the expression of IL-13 was reduced, and the expres-
sion of IL13RA2 (the soluble decoy receptor antagonist) was
increased. The functional effect of this decreased ratio of IL13/
IL13RA2 is consistent with the TH1-type inflammatory envi-
ronment evident in cases.
Tissue remodeling and fibrosis. Normal tissue structure is
maintained through the “dynamic equilibrium” of various cel-
lular processes, which build up or break down the ECM. A
change in the relative activity of these processes, in disease, can
lead to the accumulation of scar tissue. The development of
conjunctival scar tissue in trachoma is poorly understood; it is
possible that several different fibrogenic pathways contribute.
In the microarray analysis of gene expression in scarred con-
junctiva we found evidence of increased expression of several
factors that could plausibly have roles in tissue remodeling
(MMP7, MMP9, MMP12, HAS, SPARCL, and CEACAM
genes) and enrichment of fibrogenic pathways (TGF/WNT).
The matrix metalloproteinases are a family of complex en-
zymes, which are involved in a wide range of cellular processes,
including the regulation of the ECM, cytokine regulation, in-
nate immunity, and development. MMP-7 (matrilysin) had the
largest fold increase in trichiasis cases. This is consistent with
findings from The Gambia, where MMP-7 was found to be
upregulated in TT cases (30). MMP-7 is constitutively ex-
pressed in respiratory and other epithelial cells (20). Expres-
sion is increased in damaged and bacterially infected tissue. It
seems to have an important role in innate immunity, through
the activation of various components ( and 
 defensins) and
the recruitment of neutrophils.(7, 38) In addition, it regulates
epithelial wound healing; MMP-7 activates MMP-9 and de-
grades collagen-1, collagen-4, laminin, and fibronectin. MMP-7
is an important downstream gene product of signaling in the
WNT pathway.
MMP9 expression was increased in cases, particularly in the
presence of inflammation. This is consistent with earlier stud-
ies in both active and scarring trachoma, in which expression
levels correlated with the clinical inflammatory score (9, 10).
Immunohistochemistry indicates that, in children with active
trachoma, MMP-9 is found in macrophages and neutrophils
(21). We have previously described an association between a
coding polymorphism in MMP9 and reduced risk of scarring
(44). In a mouse model of chlamydial genital tract infection,
MMP-9-knockout animals had a reduced risk of scarring se-
quelae (33). Together, these observations suggest a role for
MMP-9 in the pathogenesis of trachoma. A major MMP-9
function is the degradation of type IV collagen present in the
basement membrane that disrupts the epithelium and facili-
tates the migration of cells. This is thought to be an initiating
event in epithelial-mesenchymal transition, a process whereby
epithelial cells migrate from the surface into the stroma (36).
These cells are then thought to be able to take on a fibroblast
phenotype and contribute to fibrosis. It is currently unknown
whether in trachoma the epithelium is a major source of fibro-
blasts. MMP-9 may also contribute to the development and
maintenance of inflammation. Collagen fragments are both
chemotactic and proinflammatory to monocytes and may lin-
ger for some time promoting a chronic inflammatory response
(49).
MMP12 (macrophage metalloelastase) expression was in-
creased to a similar extent in cases with or without inflamma-
tion. This is consistent with results from a murine model of
chlamydial genital infection, which showed a modest increase
in expression (54). MMP-12 is mainly produced by macro-
phages. It degrades elastin and may be proinflammatory (47).
It is prominent in respiratory tract disease such as emphysema,
where destruction of elastin is important in the pathology. It is
possible that in scarring trachoma MMP-12 is important in the
degradation of the ECM and the promotion of inflammation.
The cytokine TGF-
 is known to be important in many
scarring diseases. However, evaluation of its role in trachoma
has remained elusive, partly because of its complex posttran-
scriptional regulation. Previously, we found no variation in the
expression of TGF
2 (the dominant conjunctival isoform) be-
tween individuals with active trachoma, individuals with chla-
mydial infection, or control subjects (9). Microarray analysis
can provide some insight into the possible activity of TGF-
 by
examining downstream pathways. In the present study, indi-
viduals with trichiasis and inflammation demonstrated enrich-
ment of the TGF-
/WNT pathway. We subsequently con-
firmed, by quantitative RT-PCR, increased expression of two
downstream genes in the TGF-
/WNT pathway, NOS2A and
MMP-7, which have been found in other scarring disease pro-
cesses (68). These observations are consistent with trachoma-
tous scarring being driven at least in part by TGF-
, although
they do not provide direct since as other factors may also
increase their expression.
Limitations. Microarray analysis of the transcriptome is a
very powerful technique to simultaneously examine the tran-
scriptional activity of the genome in specific tissues. However,
describing the relative abundance of a transcript is only one
level of a complex biological process. Inferences about the
activity of some transcripts and target genes, such as TGF
,
which is central to many fibrotic processes, cannot be easily
investigated solely by this approach. Although we sampled in a
noninvasive manner from the surface, this biases the resulting
gene expression profile in favor of cells closer to the conjunc-
tival surface. However, our recent studies of in vitro confocal
microscopy indicate that most of the inflammatory cell activity
in individuals with scarring is superficial (31). Azithromycin
mass treatment had been distributed in virtually all districts
where the cases and controls lived. Although azithromycin has
a mild anti-inflammatory effect, this is probably relatively
short-lived, and we presume that in a community treatment
campaign cases and controls were equally likely to have re-
ceived treatment.
Due to the severe nature of endemic trachoma in this region
of Ethiopia, it is unusual to find older adults who do not have
any conjunctival scarring. In order to meet the various match-
ing criteria for the controls, we included individuals that had
mild scarring, as well as controls with no scarring. However, we
found only very limited evidence of any difference in gene
expression between controls without scarring and those with
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mild changes. This slight narrowing of the clinical distinction
between cases and controls would, if anything, tend to lead to
an underestimate in the size and strength of the effects mea-
sured.
Conclusions. Our findings suggest that the epithelium is not
a passive bystander in cicatricial trachoma. Several proinflam-
matory molecules probably arise from the epithelium (IL-1B,
CXCL5, and S100A7), leading to persistent recruitment of
inflammatory cells into the conjunctiva, even in the absence of
clinically visible inflammation. Various factors that are plausi-
bly involved in the production of scar tissue were also detected.
The driving force behind the responses at this stage of disease
is not apparent. Current or recent C. trachomatis infection
might have been expected to be associated with the inflamma-
tory responses. However, the prevalence of C. trachomatis was
negligible, probably reflecting the effectiveness of recent mass
antibiotic treatment campaigns. Other bacteria and environ-
mental factors could also promote inflammation in this previ-
ously damaged tissue. Longitudinal studies are needed to in-
vestigate which etiological factors and pathways are associated
with progressive scarring and whether simply controlling chla-
mydial infection will halt progression in people with estab-
lished cicatricial disease.
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